X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the partnership, Biotheus will grant Hansoh Pharma a license to use the lead product PM1080 (HS-20117) for the treatment of EGFR/c-MET expressing neoplasms and including Non-Small-Cell Lung Carcinoma.
Lead Product(s): HS-20117
Therapeutic Area: Oncology Product Name: PM1080
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 15, 2024
Details:
BioNTech will be developing, manufacturing and commercializing PM8002, a bispecific antibody candidate being evaluated in patients with advanced solid tumors, globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China.
Lead Product(s): PM8002
Therapeutic Area: Oncology Product Name: PM8002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $1,055.0 million Upfront Cash: $55.0 million
Deal Type: Licensing Agreement November 07, 2023
Details:
Under the terms of the agreement, Biotheus will grant BioNTech worldwide, exclusive options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
